BC Innovations | Mar 17, 2016
Distillery Techniques

Techniques: Human induced pluripotent stem (iPS) cell-derived models of gliomagenesis for drug screening

Disease models TECHNOLOGY: Cell models Genetically engineered human iPS cell-derived models of gliomagenesis could be used to screen therapies for brain cancer. The cell models were generated from two sets of human iPS cells by...
BioCentury | Apr 28, 2014
Strategy

Bigger is better

Novartis AG is showing every sign of continuing to think big. Ridding itself of low-performing businesses while doubling down on cancer will help the pharma increase its operating income in the short term and plug...
BC Innovations | Mar 7, 2013
Targets & Mechanisms

ALL emerges from relapse

Separate teams led by researchers from New York University and Columbia University have identified mutations in 5ʹ-nucleotidase cytosolic II that predict relapse, drug resistance and poor prognosis in acute lymphoblastic leukemia. 1,2 Inhibiting the enzyme...
BioCentury | Feb 14, 2011
Regulation

Decelerated approval

After years of hints, complaints and informal discussion, FDA has explicitly asked its Oncologic Drugs Advisory Committee - and ODAC has agreed - to raise the hurdle cancer drugs will have to clear in order to receive...
BC Extra | Jan 7, 2011
Politics & Policy

ODAC to discuss accelerated approval requirements

FDA's Oncologic Drugs Advisory Committee will meet on Feb. 8 to discuss ways to improve postmarketing trials required to confirm the benefit of drugs that received accelerated approval. The committee will review the status of...
BioCentury | Nov 15, 2010
Strategy

Innovators pick China

Five years after he co-founded BioDuro LLC , a contract research organization operating in China, John Oyler is at it again. But this time, his new team is doing what would have been almost unthinkable in...
BC Week In Review | Jan 5, 2009
Company News

Genmab, GlaxoSmithKline deal

Genmab declined to exercise its option to co-promote Arzerra ofatumumab, Bexar tositumomab and Arranon / Atriance nelarabine in exchange for a $4.5 million payment from GlaxoSmithKline that will be triggered by FDA's acceptance of the...
BioCentury | Sep 24, 2007
Strategy

Asset accumulation

Asset accumulation Product Target Indication Status Atriance nelarabine (A) DNA synthesis Lymphoblastic leukemias Mkt (Nordic rights) Bexxar tositumomab (A) CD20 Non-Hodgkin's lymphoma (NHL) Mkt (U.S. rights) HuMax-CD4 zanolimumab CD4 Cutaneous T cell lymphoma (CTCL) Ph...
BioCentury | Sep 24, 2007
Strategy

Genmab's commercial stockpile

Since the start of the year, Genmab A/S has been mulling whether to exercise an option under a 2006 deal with GlaxoSmithKline plc to co-promote cancer antibody HuMax-CD20 ofatumumab. Recent developments in two other alliances...
BC Week In Review | Jul 16, 2007
Company News

GlaxoSmithKline sales and marketing update

GSK said it does not expect to generate a profit from sales of Atriance nelarabine in Europe. The company did not disclose what the European price will be but did say that in the U.S.,...
Items per page:
1 - 10 of 19